Dronedarone

11/01/2004 - "Two recent studies on the prevention of atrial fibrillation have demonstrated that dronedarone is moderately effective with an excellent general tolerance."
01/01/2009 - "Furthermore, dronedarone, a prototypic multichannel blocker with additional effects on ventricular myocardium, has proven well tolerated and effective in the treatment of atrial fibrillation and may even reduce cardiovascular mortality. "
01/01/2010 - "The ATHENA trial demonstrated a significant reduction in cardiovascular hospitalizations and death in atrial fibrillation patients randomly assigned to receive dronedarone or placebo. "
03/01/2010 - "In two design-identical randomised clinical trials (EURIDIS and ADONIS trial) the efficacy of dronedarone to maintain sinus rhythm in patients with chronic atrial fibrillation/flutter was shown to be clearly superior to placebo. "
08/01/2012 - "Dronedarone on top of SOC appears to be a cost-effective treatment for atrial fibrillation compared with SOC alone. "

06/01/2010 - "Clinical studies have shown that dronedarone effectively reduces ventricular rate, may prevent or delay the recurrence of AF, and may reduce cardiovascular morbidity and mortality in patients with AF or atrial flutter. "
09/01/2009 - "Phase III clinical trials have shown dronedarone to be effective at reducing ventricular rate, reducing recurrence of AF, and reducing cardiovascular morbidity and mortality in patients with AF or atrial flutter (AFL). "
08/20/2009 - "Oral dronedarone was generally well tolerated in the treatment of adult patients with AF and/or atrial flutter in clinical studies. "
05/01/2013 - "In conclusion, dronedarone is associated with frequent adverse events and moderate antiarrhythmic efficacy requiring discontinuation in most patients within the first 9 months of use, and there is a prevalent reversal from persistent to paroxysmal but also from paroxysmal to persistent atrial arrhythmias and from AF to non-isthmus-dependent atrial flutter."
01/01/2008 - "More than 4,600 patients with a history of AF or atrial flutter (AFL) have been randomized to receive dronedarone 400 mg bid or matching placebo. "

04/07/2010 - "Secondly, according to a post hoc analysis a significant reduction in stroke was observed (annual rate 1.2% on dronedarone vs 1.8% on placebo, respectively [hazard ratio 0.66, confidence interval 0.46 to 0.96, P = 0.027]). "
03/28/2015 - "None of them found any significant difference with the exception of a single trial than found less strokes in the group treated with dronedarone compared to placebo. "
12/01/2011 - "In the random effects model, the statistical weight of the ATHENA trial was much lower (45.1%) and the RD for stroke or TIA between the dronedarone and the placebo groups did not reach statistical significance (RD -0.0064, 95% CI -0.0144, 0.0016; p = 0.120). "
12/01/2011 - "The RD of the incidence of stroke or TIA in all trials between patients randomized to dronedarone and those randomized to placebo was -0.0094 (95% confidence interval [CI] -0.0178, -0.0011; p = 0.027). "
12/01/2011 - "160 strokes or TIAs were reported in the four trials: 67 in the dronedarone group (2.1%) and 93 in the placebo group (3.3%). "

10/01/2009 - "Conversely, the recently published ATHENA study (including more than 4,600 high risk patients, but excluding those with severe heart failure) demonstrated a significant reduction in cardiovascular hospitalizations and cardiovascular mortality with dronedarone compared to placebo. "
04/01/2019 - "Sensitivity analyses then showed that the exclusion of a study, namely ATHENA study, caused a shift in the overall odds ratio, so as to convert the dronedarone use to the ominous role of predictor of higher mortality, worse cardiovascular morbidity and increased risk of worsening heart failure. "
04/01/2019 - "In addition, when data from ATHENA study were excluded, dronedarone use was associated with increased all-cause mortality (post exclusion pooled odds ratio=1.77; 95% CI: 1.15 to 2.72; P=0.0089), increased risk of major cardiovascular events (post exclusion pooled odds ratio=2.16; 95% CI: 1.34 to 3.47; P= 0.0014) and increased risk of worsening heart failure(post exclusion pooled odds ratio= 1.618; 95% CI: 1.14 to 2.3; P=0.006). "
08/01/2013 - "In the ATHENA trial, dronedarone was used in elderly high risk patients with paroxysmal or persistent AF/AFl, excluding those with advanced heart failure, cardiovascular hospitalizations were significantly reduced. "
08/01/2013 - "In the ANDROMEDA trial, dronedarone treatment increased mortality and cardiovascular hospitalizations patients with decompensated heart failure. "

09/06/2007 - "Dronedarone was significantly more effective than placebo in maintaining sinus rhythm and in reducing the ventricular rate during recurrence of arrhythmia."
09/06/2007 - "At the recurrence of arrhythmia in the European trial, the mean (+/-SD) ventricular rate was 117.5+/-29.1 beats per minute in the placebo group and 102.3+/-24.7 beats per minute in the dronedarone group (P<0.001); the corresponding rates in the non-European trial were 116.6+/-31.9 and 104.6+/-27.1 beats per minute (P<0.001). "
09/06/2007 - "In the European trial, the median times to the recurrence of arrhythmia were 41 days in the placebo group and 96 days in the dronedarone group (P=0.01). "
09/13/2019 - "The objective of this research is to prepare filaments containing dronedarone hydrochloride, a drug used in the treatment of cardiac arrhythmias. "
01/01/2018 - "Dronedarone is used to treat patients with cardiac arrhythmias and has been reported to be associated with liver injury. "